Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like TumorTranslational Oncology.  14. 2021
2021 Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenograftsJournal of Pediatric Surgery.  56:1165-1173. 2021
2021 PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastomaJournal of Pediatric Surgery.  56:1157-1164. 2021
2021 Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group 2021
2021 EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growthPLoS ONE.  16. 2021
2021 9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenograftsTranslational Oncology.  14. 2021
2021 To Disclose or Not to Disclose: A Case Highlighting the Challenge of Conflicts in Pediatric DisclosureJournal of Pain and Symptom Management.  61:211-215. 2021
2020 Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group 2020
2020 Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features 2020
2019 Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived XenograftsScientific Reports.  9. 2019
2019 Corruption of neuroblastoma patient derived xenografts with human T cell lymphomaJournal of Pediatric Surgery.  54:2117-2119. 2019
2019 UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line XenograftsTranslational Oncology.  12:1364-1374. 2019
2019 The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survivalJournal of Pediatric Surgery.  54:1206-1213. 2019
2019 PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cellsPLoS ONE.  14. 2019
2019 Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in HepatoblastomaTranslational Oncology.  12:200-208. 2019
2019 Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor GrowthTranslational Oncology.  12:84-95. 2019
2019 The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumorOncotarget.  10:5534-5548. 2019
2018 FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived XenograftsScientific Reports.  8. 2018
2018 UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenograftsJournal of Neuro-Oncology.  140:209-224. 2018
2018 Targeting PIM kinase as a therapeutic strategy in human hepatoblastomaOncotarget.  9:22665-22679. 2018
2008 Effects of disrupting calcium homeostasis on neuronal maturation: early inhibition and later recovery.Cellular and Molecular Neurobiology.  28:389-409. 2008

Chapter

Year Title Altmetric
2019 Role of stemness factors in neuroblastoma.  187-202. 2019

Investigator On

  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION  awarded by CHILDREN'S ONCOLOGY GROUP
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase ll Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Development, Maintenance and Utilization of a Pediatric Solid Tumor Xenograft Bank  awarded by THE CHILDREN'S HOSPITAL OF ALABAMA
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • MCC 18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 18613, Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 20339 Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Phase 1-11 Study of MEK 162 for Children with Progressive or Recurrent Cancer and A Phase 11 Study of Children with Low- Grade Gliomas and Other Ras/ RAF/MAP Pathway Activated Tumors  awarded by CHILDREN'S HOSPITAL LA
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by EISAI, INC.
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Transforming Pediatric Oncology Healthcare Through Family Navigation  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Education And Training

  • Doctor of Medicine, Mercer University 2012
  • Full Name

  • Jamie Aye